Boston medical-technology company expands its portfolio with the purchase of Attune Medical
- Haemonetics to acquire Attune Medical for $160 million in cash
- Deal includes additional contingent milestone-based consideration over three years
- Funding for the acquisition will come from cash on hand and a draw under Haemonetics’ revolving credit facility
- Attune Medical generated approximately $22 million in revenue last year
- ensoETM is the only FDA-approved temperature-regulation device for esophageal protection during radiofrequency cardiac ablation procedures
- Acquisition expected to be completed in the first quarter of Haemonetics’ 2025 fiscal year
Haemonetics, a Boston-based medical-technology company, has announced its acquisition of Attune Medical for an initial cash payment of $160 million. The deal also includes additional contingent milestone-based consideration over three years. The funding for the acquisition will be sourced from Haemonetics’ cash reserves and a draw under its revolving credit facility. Attune Medical, the maker of the ensoETM esophageal cooling device, generated approximately $22 million in revenue last year. The ensoETM is the only FDA-approved temperature-regulation device indicated for esophageal protection during radiofrequency cardiac ablation procedures. The acquisition is expected to be completed in the first quarter of Haemonetics’ 2025 fiscal year.
Factuality Level: 9
Factuality Justification: The article provides factual information about Haemonetics acquiring Attune Medical, including the purchase amount, funding details, revenue generated by Attune Medical, and the FDA approval for ensoETM device. The article does not contain any irrelevant information, misleading details, sensationalism, redundancy, or opinion masquerading as fact. It is concise and focused on the main topic.
Noise Level: 3
Noise Justification: The article provides relevant information about Haemonetics acquiring Attune Medical, including the deal amount, funding plans, revenue generated by Attune Medical, and details about the ensoETM device. The article stays on topic and does not contain irrelevant or misleading information. However, it lacks in-depth analysis, antifragility considerations, accountability exploration, and actionable insights, which prevent it from scoring higher.
Financial Relevance: Yes
Financial Markets Impacted: The financial markets may be impacted by Haemonetics’ acquisition of Attune Medical. Investors and shareholders of both companies may be affected by the deal.
Presence Of Extreme Event: No
Nature Of Extreme Event: No
Impact Rating Of The Extreme Event: No
Rating Justification: The news article does not mention any extreme events or their impact. It primarily focuses on Haemonetics’ acquisition of Attune Medical and the financial implications of the deal.
Public Companies: Haemonetics (HAE)
Private Companies: Attune Medical
Key People: Colin Kellaher (Author)
Reported publicly:
www.marketwatch.com 
